IP Library Granted Patent US 10,722,245
Granted Patent B2
US 10,722,245 · App. 16/254,589 · Granted Jul 28, 2020

Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant

Inventor: Samir Bipin Pancholy (Clarks Summit, PA)
Assignee: VASOINNOVATIONS INC.
A61B17/1325A61B17/12A61B17/135A61B2017/12004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,722,245
App. No.
16/254,589
Granted
Jul 28, 2020
Kind
B2
Abstract

Disclosed is a method of reducing a dosage of an anticoagulant when performing a catheterization procedure at an access site of an artery. The method comprises administering the anticoagulant at a dose less than a conventional dose, reducing a contact time of blood at the access site of the artery, and maintaining the contact time of blood at a reduced level for a period of time during the catheterization procedure.

Claims (17)

1. A method to attain patent hemostasis of a femoral artery when performing a catheterization procedure involving the femoral artery that is punctured at an access site thereof, comprising:

administering an anticoagulant, wherein a dosage of the anticoagulant is less than an equivalent of 50 units of unfractionated heparin per kg of body weight;

reducing a contact time of blood at the access site by increasing a velocity of blood in the femoral artery; and

maintaining the increased velocity of blood in the femoral artery for a period of time during the catheterization procedure;

attaining patent hemostasis of the femoral artery.

2. The method of claim 1 , wherein said velocity of blood is increased by increasing a flow of blood in the femoral artery.

3. The method of claim 2 , wherein the flow of blood in the femoral artery is increased by using a pump.

4. The method of claim 1 , wherein the period of time is less than 120 minutes.

5. The method of claim 4 , wherein the dosage of the anticoagulant is in a range from an equivalent of about 15 units of unfractionated heparin per kg of body weight to an equivalent of about 30 units of unfractionated heparin per kg of body weight.

6. The method of claim 4 , wherein the dosage of the anticoagulant is in a range from an equivalent of about 20 units of unfractionated heparin per kg of body weight to an equivalent of about 40 units of unfractionated heparin per kg of body weight.

7. The method of claim 4 , wherein the dosage of the anticoagulant is less than an equivalent of 25 units of unfractionated heparin per kg of body weight.

8. The method of claim 1 , wherein the period of time is less than 60 minutes.

9. The method of claim 8 , wherein the dosage of the anticoagulant is in a range from an equivalent of about 15 units of unfractionated heparin per kg of body weight to an equivalent of about 30 units of unfractionated heparin per kg of body weight.

10. The method of claim 8 , wherein the dosage of the anticoagulant is in a range from an equivalent of about 20 units of unfractionated heparin per kg of body weight to an equivalent of about 40 units of unfractionated heparin per kg of body weight.

11. The method of claim 8 , wherein the dosage of the anticoagulant is less than an equivalent of 25 units of unfractionated heparin per kg of body weight.

12. The method of claim 8 , wherein the anticoagulant is selected from a group consisting of: heparin, dalteparin, danaparoid, enoxaparin, unfractionated heparin, low molecular weight heparin, direct thrombin inhibitors including hirudin, argatroban, bivalirudin, and combinations or derivatives thereof.

13. The method of claim 1 , wherein the anticoagulant is selected from a group consisting of: heparin, dalteparin, danaparoid, enoxaparin, unfractionated heparin, low molecular weight heparin, direct thrombin inhibitors including hirudin, argatroban, bivalirudin, and combinations or derivatives thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2019
From: PANCHOLY, SAMIR BIPIN, DR
To: VASOINNOVATIONS INC.
Reel/Frame 048975/0996 →
Continuity (10)
Division 16138958 · Sep 21, 2018
Continuation In Part 15708123 · Sep 18, 2017
Continuation In Part 15426056 · Feb 7, 2017
Continuation In Part 15340023 · Nov 1, 2016
Continuation 15062150 · Mar 6, 2016
Continuation 13941219 · Jul 12, 2013
Provisional Application 62653172 · Apr 5, 2018
Provisional Application 62549923 · Aug 24, 2017
Provisional Application 62405951 · Oct 9, 2016
Related Publication 20190150940A1 · May 23, 2019
Cited By (1)
US 12,733,935